SG188144A1 - Alpha 7 nicotinic agonists and antipsychotics - Google Patents

Info

Publication number

SG188144A1

SG188144A1 SG2013010327A SG2013010327A SG188144A1 SG 188144 A1 SG188144 A1 SG 188144A1 SG 2013010327 A SG2013010327 A SG 2013010327A SG 2013010327 A SG2013010327 A SG 2013010327A SG 188144 A1 SG188144 A1 SG 188144A1

Authority

SG

Singapore

Prior art keywords

oct

pyridinyl

methyl

azabicyclo

carboxamide

Prior art date

2008-02-13

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000181 nicotinic agonist Substances 0.000 title claims abstract description 67
• 239000000164 antipsychotic agent Substances 0.000 title claims abstract description 31
• 229940005529 antipsychotics Drugs 0.000 title description 12
• KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 103
• 201000000980 schizophrenia Diseases 0.000 claims description 95
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 87
• 150000001875 compounds Chemical class 0.000 claims description 81
• 150000003839 salts Chemical class 0.000 claims description 66
• 239000004202 carbamide Substances 0.000 claims description 57
• 239000003814 drug Substances 0.000 claims description 55
• 238000011282 treatment Methods 0.000 claims description 50
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
• 239000012453 solvate Substances 0.000 claims description 45
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 44
• 230000000561 anti-psychotic effect Effects 0.000 claims description 41
• 229960004170 clozapine Drugs 0.000 claims description 41
• 238000000034 method Methods 0.000 claims description 40
• -1 any Chemical group 0.000 claims description 38
• 230000006735 deficit Effects 0.000 claims description 35
• 208000028017 Psychotic disease Diseases 0.000 claims description 32
• 229960004431 quetiapine Drugs 0.000 claims description 32
• URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 32
• 208000035475 disorder Diseases 0.000 claims description 31
• 239000000556 agonist Substances 0.000 claims description 26
• 125000003118 aryl group Chemical group 0.000 claims description 24
• 208000020016 psychiatric disease Diseases 0.000 claims description 24
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 21
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 20
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 19
• 229910052760 oxygen Inorganic materials 0.000 claims description 19
• 239000001301 oxygen Substances 0.000 claims description 19
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
• 239000003693 atypical antipsychotic agent Substances 0.000 claims description 16
• 229940127236 atypical antipsychotics Drugs 0.000 claims description 16
• 239000003795 chemical substances by application Substances 0.000 claims description 15
• 239000002207 metabolite Substances 0.000 claims description 14
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 13
• QHKJIJXBJCOABP-UHFFFAOYSA-N 1-benzofuran-2-carboxamide Chemical compound C1=CC=C2OC(C(=O)N)=CC2=C1 QHKJIJXBJCOABP-UHFFFAOYSA-N 0.000 claims description 11
• 229910052757 nitrogen Inorganic materials 0.000 claims description 11
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 10
• 125000000623 heterocyclic group Chemical group 0.000 claims description 10
• 125000000217 alkyl group Chemical group 0.000 claims description 9
• 230000002265 prevention Effects 0.000 claims description 9
• NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 claims description 8
• 229960002419 flupentixol Drugs 0.000 claims description 8
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 8
• 230000002195 synergetic effect Effects 0.000 claims description 7
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
• 229960005017 olanzapine Drugs 0.000 claims description 6
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 6
• 238000002360 preparation method Methods 0.000 claims description 6
• 229960001534 risperidone Drugs 0.000 claims description 6
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 6
• 229960000652 sertindole Drugs 0.000 claims description 6
• GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims description 6
• 238000002560 therapeutic procedure Methods 0.000 claims description 6
• MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 6
• CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 claims description 5
• NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims description 5
• 229950009087 bifeprunox Drugs 0.000 claims description 5
• 229960003878 haloperidol Drugs 0.000 claims description 5
• 125000001072 heteroaryl group Chemical group 0.000 claims description 5
• 125000005842 heteroatom Chemical group 0.000 claims description 5
• 125000003107 substituted aryl group Chemical group 0.000 claims description 5
• 208000024254 Delusional disease Diseases 0.000 claims description 4
• RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
• 208000019568 Shared Paranoid disease Diseases 0.000 claims description 4
• 208000028810 Shared psychotic disease Diseases 0.000 claims description 4
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
• 125000003342 alkenyl group Chemical group 0.000 claims description 4
• 229960003036 amisulpride Drugs 0.000 claims description 4
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 4
• 229960001076 chlorpromazine Drugs 0.000 claims description 4
• 229910052736 halogen Inorganic materials 0.000 claims description 4
• 150000002367 halogens Chemical class 0.000 claims description 4
• 230000010365 information processing Effects 0.000 claims description 4
• 208000002851 paranoid schizophrenia Diseases 0.000 claims description 4
• 229960000762 perphenazine Drugs 0.000 claims description 4
• 229910052717 sulfur Chemical group 0.000 claims description 4
• 239000011593 sulfur Chemical group 0.000 claims description 4
• DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 claims description 4
• 208000021465 Brief psychotic disease Diseases 0.000 claims description 3
• 125000001188 haloalkyl group Chemical group 0.000 claims description 3
• 229910052739 hydrogen Inorganic materials 0.000 claims description 3
• 239000001257 hydrogen Substances 0.000 claims description 3
• 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
• 208000022610 schizoaffective disease Diseases 0.000 claims description 3
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
• 229960004496 zotepine Drugs 0.000 claims description 3
• HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 claims description 3
• PVICREAWTADNSB-UHFFFAOYSA-N (2,4-dimethoxyphenyl)carbamic acid Chemical compound COC1=CC=C(NC(O)=O)C(OC)=C1 PVICREAWTADNSB-UHFFFAOYSA-N 0.000 claims description 2
• FTLCLAFMYWOANF-UHFFFAOYSA-N (2-fluorophenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC=C1F FTLCLAFMYWOANF-UHFFFAOYSA-N 0.000 claims description 2
• VTAQLGRULYHNQX-UHFFFAOYSA-N (3,4-dichlorophenyl)carbamic acid Chemical compound OC(=O)NC1=CC=C(Cl)C(Cl)=C1 VTAQLGRULYHNQX-UHFFFAOYSA-N 0.000 claims description 2
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
• 125000004429 atom Chemical group 0.000 claims description 2
• 150000003857 carboxamides Chemical class 0.000 claims description 2
• RYWLIWRIMUYNQS-UHFFFAOYSA-N naphthalen-1-ylcarbamic acid Chemical compound C1=CC=C2C(NC(=O)O)=CC=CC2=C1 RYWLIWRIMUYNQS-UHFFFAOYSA-N 0.000 claims description 2
• MNYCZTMXYXZNIJ-UHFFFAOYSA-N naphthalene-1-carboxamide Chemical compound C1=CC=C[C]2C(C(=O)N)=C=CC=C21 MNYCZTMXYXZNIJ-UHFFFAOYSA-N 0.000 claims description 2
• 239000011885 synergistic combination Substances 0.000 claims description 2
• VNMLVHLVBFHHSN-UHFFFAOYSA-N thiophen-2-ylcarbamic acid Chemical compound OC(=O)NC1=CC=CS1 VNMLVHLVBFHHSN-UHFFFAOYSA-N 0.000 claims description 2
• LSGKMZLPZFPAIN-UHFFFAOYSA-N 1h-indole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CNC2=C1 LSGKMZLPZFPAIN-UHFFFAOYSA-N 0.000 claims 2
• OAQKFULUNYIBBR-UHFFFAOYSA-N (2-chlorophenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC=C1Cl OAQKFULUNYIBBR-UHFFFAOYSA-N 0.000 claims 1
• QXAICYQHORWBRC-UHFFFAOYSA-N (2-cyanophenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC=C1C#N QXAICYQHORWBRC-UHFFFAOYSA-N 0.000 claims 1
• AXVPVXHGWJWEPI-UHFFFAOYSA-N (2-methylphenyl)carbamic acid Chemical compound CC1=CC=CC=C1NC(O)=O AXVPVXHGWJWEPI-UHFFFAOYSA-N 0.000 claims 1
• CCBMTBNWUDKADX-UHFFFAOYSA-N (2-phenoxyphenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC=C1OC1=CC=CC=C1 CCBMTBNWUDKADX-UHFFFAOYSA-N 0.000 claims 1
• OAYMUOAVUHJSNG-UHFFFAOYSA-N (3-bromophenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC(Br)=C1 OAYMUOAVUHJSNG-UHFFFAOYSA-N 0.000 claims 1
• VZAZTNWSVRVMDP-UHFFFAOYSA-N (3-fluorophenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC(F)=C1 VZAZTNWSVRVMDP-UHFFFAOYSA-N 0.000 claims 1
• LQMWWRSOANZFNV-UHFFFAOYSA-N (3-methoxyphenyl)carbamic acid Chemical compound COC1=CC=CC(NC(O)=O)=C1 LQMWWRSOANZFNV-UHFFFAOYSA-N 0.000 claims 1
• DMRVIRJPXTULLZ-UHFFFAOYSA-N (3-phenoxyphenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC(OC=2C=CC=CC=2)=C1 DMRVIRJPXTULLZ-UHFFFAOYSA-N 0.000 claims 1
• VZQDNZQCQKJHNO-UHFFFAOYSA-N (4-methoxyphenyl)carbamic acid Chemical compound COC1=CC=C(NC(O)=O)C=C1 VZQDNZQCQKJHNO-UHFFFAOYSA-N 0.000 claims 1
• RHNSSYGTJAAVCR-UHFFFAOYSA-N (4-methylphenyl)carbamic acid Chemical compound CC1=CC=C(NC(O)=O)C=C1 RHNSSYGTJAAVCR-UHFFFAOYSA-N 0.000 claims 1
• WDCXLHAUHFGKOF-UHFFFAOYSA-N 1-(3-bromophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound BrC1=CC=CC(NC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 WDCXLHAUHFGKOF-UHFFFAOYSA-N 0.000 claims 1
• HKAXJWRSTUXFSC-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound ClC1=CC=CC(NC(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 HKAXJWRSTUXFSC-UHFFFAOYSA-N 0.000 claims 1
• VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical compound C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 claims 1
• XANDONBYNOJINR-UHFFFAOYSA-N 2-bromo-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound BrC1=CC=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 XANDONBYNOJINR-UHFFFAOYSA-N 0.000 claims 1
• RZPIJBPBVDWNPW-UHFFFAOYSA-N 2-methyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzenecarbothioamide Chemical compound CC1=CC=CC=C1C(=S)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 RZPIJBPBVDWNPW-UHFFFAOYSA-N 0.000 claims 1
• HOZJFAKGWYDDEG-UHFFFAOYSA-N 2-phenyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 HOZJFAKGWYDDEG-UHFFFAOYSA-N 0.000 claims 1
• IQHVZSLMNJEPST-UHFFFAOYSA-N 3-(4-methoxyphenyl)-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C1=CC(OC)=CC=C1C=CC(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 IQHVZSLMNJEPST-UHFFFAOYSA-N 0.000 claims 1
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
• YKYDSKNIBFBZME-UHFFFAOYSA-N 3-phenyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C=1C=CC(C=2C=CC=CC=2)=CC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 YKYDSKNIBFBZME-UHFFFAOYSA-N 0.000 claims 1
• BHMFKHWVYBKHMM-UHFFFAOYSA-N 3-phenyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]but-2-enamide Chemical compound C=1C=CC=CC=1C(C)=CC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 BHMFKHWVYBKHMM-UHFFFAOYSA-N 0.000 claims 1
• 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
• 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
• WLVOAUDOALHRRO-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(3-cyanophenyl)carbamate Chemical compound C1CC2CCN1C(CC=1C=NC=CC=1)C2OC(=O)NC1=CC=CC(C#N)=C1 WLVOAUDOALHRRO-UHFFFAOYSA-N 0.000 claims 1
• OSIDHOSKWJZDAH-UHFFFAOYSA-N [4-(dimethylamino)phenyl]carbamic acid Chemical compound CN(C)C1=CC=C(NC(O)=O)C=C1 OSIDHOSKWJZDAH-UHFFFAOYSA-N 0.000 claims 1
• 125000005605 benzo group Chemical group 0.000 claims 1
• LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims 1
• JVXXKQIRGQDWOJ-UHFFFAOYSA-N naphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CC=C21 JVXXKQIRGQDWOJ-UHFFFAOYSA-N 0.000 claims 1
• PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical compound OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 claims 1
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 154
• 241000699670 Mus sp. Species 0.000 description 130
• 229960003638 dopamine Drugs 0.000 description 77
• 230000000694 effects Effects 0.000 description 73
• 229940126062 Compound A Drugs 0.000 description 69
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 69
• 238000012360 testing method Methods 0.000 description 59
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 50
• 230000006977 prepulse inhibition Effects 0.000 description 48
• 210000004556 brain Anatomy 0.000 description 46
• 210000002569 neuron Anatomy 0.000 description 40
• 239000000203 mixture Substances 0.000 description 35
• 102000005962 receptors Human genes 0.000 description 35
• 108020003175 receptors Proteins 0.000 description 35
• 208000024891 symptom Diseases 0.000 description 35
• 210000004515 ventral tegmental area Anatomy 0.000 description 32
• 229940079593 drug Drugs 0.000 description 31
• 241001465754 Metazoa Species 0.000 description 30
• 241000700159 Rattus Species 0.000 description 28
• 239000000835 fiber Substances 0.000 description 23
• 230000001537 neural effect Effects 0.000 description 23
• 241000699660 Mus musculus Species 0.000 description 22
• 210000003523 substantia nigra Anatomy 0.000 description 22
• 238000011830 transgenic mouse model Methods 0.000 description 22
• 229940124597 therapeutic agent Drugs 0.000 description 21
• 230000036278 prepulse Effects 0.000 description 20
• 230000004044 response Effects 0.000 description 20
• 210000004940 nucleus Anatomy 0.000 description 19
• 239000003981 vehicle Substances 0.000 description 18
• 230000024188 startle response Effects 0.000 description 17
• 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 16
• 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 16
• 230000006399 behavior Effects 0.000 description 16
• 229960002715 nicotine Drugs 0.000 description 16
• 230000009151 sensory gating Effects 0.000 description 16
• 230000009261 transgenic effect Effects 0.000 description 16
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
• 210000004369 blood Anatomy 0.000 description 15
• 239000008280 blood Substances 0.000 description 15
• 210000004027 cell Anatomy 0.000 description 15
• 230000006870 function Effects 0.000 description 15
• 230000001965 increasing effect Effects 0.000 description 15
• 230000027455 binding Effects 0.000 description 14
• 230000001054 cortical effect Effects 0.000 description 14
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 14
• 230000001225 therapeutic effect Effects 0.000 description 14
• 206010012601 diabetes mellitus Diseases 0.000 description 13
• 235000013305 food Nutrition 0.000 description 13
• HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 description 12
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 12
• 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 12
• 201000010099 disease Diseases 0.000 description 12
• 230000000862 serotonergic effect Effects 0.000 description 12
• 238000004458 analytical method Methods 0.000 description 11
• 238000011161 development Methods 0.000 description 11
• 230000018109 developmental process Effects 0.000 description 11
• 239000008194 pharmaceutical composition Substances 0.000 description 11
• 239000011780 sodium chloride Substances 0.000 description 11
• DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 10
• 238000000540 analysis of variance Methods 0.000 description 10
• 230000005764 inhibitory process Effects 0.000 description 10
• 230000003993 interaction Effects 0.000 description 10
• 210000001259 mesencephalon Anatomy 0.000 description 10
• 230000004913 activation Effects 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 230000000698 schizophrenic effect Effects 0.000 description 9
• 229940076279 serotonin Drugs 0.000 description 9
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 8
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
• 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 8
• 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 8
• 238000010171 animal model Methods 0.000 description 8
• 230000007423 decrease Effects 0.000 description 8
• 239000008103 glucose Substances 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 238000011835 investigation Methods 0.000 description 8
• 230000007246 mechanism Effects 0.000 description 8
• 210000001577 neostriatum Anatomy 0.000 description 8
• 108090000623 proteins and genes Proteins 0.000 description 8
• 230000011273 social behavior Effects 0.000 description 8
• 230000003936 working memory Effects 0.000 description 8
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 208000021017 Weight Gain Diseases 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 7
• 229960004046 apomorphine Drugs 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 230000008765 hyperinnervation Effects 0.000 description 7
• 230000001771 impaired effect Effects 0.000 description 7
• 239000003446 ligand Substances 0.000 description 7
• 239000010445 mica Substances 0.000 description 7
• 229910052618 mica group Inorganic materials 0.000 description 7
• 210000002381 plasma Anatomy 0.000 description 7
• 210000002442 prefrontal cortex Anatomy 0.000 description 7
• 230000011664 signaling Effects 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 235000019786 weight gain Nutrition 0.000 description 7
• RPYWXZCFYPVCNQ-RVDMUPIBSA-N DMXB-A Chemical compound COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 RPYWXZCFYPVCNQ-RVDMUPIBSA-N 0.000 description 6
• 108091008794 FGF receptors Proteins 0.000 description 6
• 208000026139 Memory disease Diseases 0.000 description 6
• 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 6
• 239000005557 antagonist Substances 0.000 description 6
• 230000003542 behavioural effect Effects 0.000 description 6
• 210000003169 central nervous system Anatomy 0.000 description 6
• 230000019771 cognition Effects 0.000 description 6
• 210000005153 frontal cortex Anatomy 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 230000015654 memory Effects 0.000 description 6
• 210000001009 nucleus accumben Anatomy 0.000 description 6
• 235000021251 pulses Nutrition 0.000 description 6
• 230000002739 subcortical effect Effects 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• 230000004584 weight gain Effects 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 5
• 206010012239 Delusion Diseases 0.000 description 5
• 208000032928 Dyslipidaemia Diseases 0.000 description 5
• 108010010803 Gelatin Proteins 0.000 description 5
• 208000004547 Hallucinations Diseases 0.000 description 5
• 208000017170 Lipid metabolism disease Diseases 0.000 description 5
• 230000002159 abnormal effect Effects 0.000 description 5
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 5
• 229960004373 acetylcholine Drugs 0.000 description 5
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 231100000868 delusion Toxicity 0.000 description 5
• 230000003292 diminished effect Effects 0.000 description 5
• 239000003937 drug carrier Substances 0.000 description 5
• 230000009977 dual effect Effects 0.000 description 5
• 235000019441 ethanol Nutrition 0.000 description 5
• 239000008273 gelatin Substances 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• 230000002068 genetic effect Effects 0.000 description 5
• 210000001320 hippocampus Anatomy 0.000 description 5
• 208000013403 hyperactivity Diseases 0.000 description 5
• 230000001096 hypoplastic effect Effects 0.000 description 5
• 230000001976 improved effect Effects 0.000 description 5
• 125000002950 monocyclic group Chemical group 0.000 description 5
• 230000037361 pathway Effects 0.000 description 5
• 238000006467 substitution reaction Methods 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• 229960000607 ziprasidone Drugs 0.000 description 5
• VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 4
• CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 4
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 4
• 240000007472 Leucaena leucocephala Species 0.000 description 4
• 229940123925 Nicotinic receptor agonist Drugs 0.000 description 4
• 244000046052 Phaseolus vulgaris Species 0.000 description 4
• 235000010627 Phaseolus vulgaris Nutrition 0.000 description 4
• 229920005372 Plexiglas® Polymers 0.000 description 4
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 238000000692 Student's t-test Methods 0.000 description 4
• 101710128896 Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 4
• 206010046996 Varicose vein Diseases 0.000 description 4
• 239000012190 activator Substances 0.000 description 4
• 229960005245 asenapine Drugs 0.000 description 4
• 230000007278 cognition impairment Effects 0.000 description 4
• 208000010877 cognitive disease Diseases 0.000 description 4
• 230000001149 cognitive effect Effects 0.000 description 4
• 210000003618 cortical neuron Anatomy 0.000 description 4
• 230000002950 deficient Effects 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 210000004295 hippocampal neuron Anatomy 0.000 description 4
• 125000005647 linker group Chemical group 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 210000003205 muscle Anatomy 0.000 description 4
• 239000003176 neuroleptic agent Substances 0.000 description 4
• 230000000701 neuroleptic effect Effects 0.000 description 4
• 239000002858 neurotransmitter agent Substances 0.000 description 4
• 210000000287 oocyte Anatomy 0.000 description 4
• 238000012346 open field test Methods 0.000 description 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
• 125000003367 polycyclic group Chemical group 0.000 description 4
• 239000004926 polymethyl methacrylate Substances 0.000 description 4
• 125000004076 pyridyl group Chemical group 0.000 description 4
• 210000001609 raphe nuclei Anatomy 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 230000000391 smoking effect Effects 0.000 description 4
• 239000008107 starch Substances 0.000 description 4
• 229940032147 starch Drugs 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 3
• 241000416162 Astragalus gummifer Species 0.000 description 3
• 108010077544 Chromatin Proteins 0.000 description 3
• 208000028698 Cognitive impairment Diseases 0.000 description 3
• 206010011953 Decreased activity Diseases 0.000 description 3
• 208000027776 Extrapyramidal disease Diseases 0.000 description 3
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 3
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
• 102100031775 Leptin receptor Human genes 0.000 description 3
• 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 229930040373 Paraformaldehyde Natural products 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 241000290149 Scapteriscus didactylus Species 0.000 description 3
• 206010041243 Social avoidant behaviour Diseases 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 241000011102 Thera Species 0.000 description 3
• 229920001615 Tragacanth Polymers 0.000 description 3
• 229960004372 aripiprazole Drugs 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
• 230000005540 biological transmission Effects 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 210000005013 brain tissue Anatomy 0.000 description 3
• 210000003483 chromatin Anatomy 0.000 description 3
• 239000012050 conventional carrier Substances 0.000 description 3
• 230000003291 dopaminomimetic effect Effects 0.000 description 3
• 230000000763 evoking effect Effects 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 230000002349 favourable effect Effects 0.000 description 3
• 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 3
• 230000000971 hippocampal effect Effects 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 230000013016 learning Effects 0.000 description 3
• 108010019813 leptin receptors Proteins 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 230000033001 locomotion Effects 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 3
• 230000003278 mimic effect Effects 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 230000001123 neurodevelopmental effect Effects 0.000 description 3
• 235000014571 nuts Nutrition 0.000 description 3
• 238000001543 one-way ANOVA Methods 0.000 description 3
• 229920002866 paraformaldehyde Polymers 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 238000004445 quantitative analysis Methods 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 238000007634 remodeling Methods 0.000 description 3
• 230000031893 sensory processing Effects 0.000 description 3
• 230000003997 social interaction Effects 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 235000010356 sorbitol Nutrition 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 239000000375 suspending agent Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 230000009044 synergistic interaction Effects 0.000 description 3
• 235000020357 syrup Nutrition 0.000 description 3
• 239000006188 syrup Substances 0.000 description 3
• 238000012353 t test Methods 0.000 description 3
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 235000010487 tragacanth Nutrition 0.000 description 3
• 239000000196 tragacanth Substances 0.000 description 3
• 229940116362 tragacanth Drugs 0.000 description 3
• 238000012549 training Methods 0.000 description 3
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
• DIVQKHQLANKJQO-UHFFFAOYSA-N 3-methoxytyramine Chemical compound COC1=CC(CCN)=CC=C1O DIVQKHQLANKJQO-UHFFFAOYSA-N 0.000 description 2
• PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 2
• 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 2
• ODPOAESBSUKMHD-UHFFFAOYSA-L 6,7-dihydrodipyrido[1,2-b:1',2'-e]pyrazine-5,8-diium;dibromide Chemical compound [Br-].[Br-].C1=CC=[N+]2CC[N+]3=CC=CC=C3C2=C1 ODPOAESBSUKMHD-UHFFFAOYSA-L 0.000 description 2
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 241001573498 Compacta Species 0.000 description 2
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• 238000011765 DBA/2 mouse Methods 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 239000005630 Diquat Substances 0.000 description 2
• 208000003098 Ganglion Cysts Diseases 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 2
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• 102000043136 MAP kinase family Human genes 0.000 description 2
• 108091054455 MAP kinase family Proteins 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 101100382264 Mus musculus Ca14 gene Proteins 0.000 description 2
• 101100112373 Mus musculus Ctsm gene Proteins 0.000 description 2
• 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
• 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• 101100094962 Salmo salar salarin gene Proteins 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 2
• 208000005400 Synovial Cyst Diseases 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
• 241000269370 Xenopus <genus> Species 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000008186 active pharmaceutical agent Substances 0.000 description 2
• 229940072056 alginate Drugs 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 210000004727 amygdala Anatomy 0.000 description 2
• 230000008485 antagonism Effects 0.000 description 2
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
• 210000004227 basal ganglia Anatomy 0.000 description 2
• 230000006736 behavioral deficit Effects 0.000 description 2
• 208000013404 behavioral symptom Diseases 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 230000004641 brain development Effects 0.000 description 2
• 230000003925 brain function Effects 0.000 description 2
• 238000009395 breeding Methods 0.000 description 2
• 230000001488 breeding effect Effects 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 238000001218 confocal laser scanning microscopy Methods 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 229940095074 cyclic amp Drugs 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 2
• 230000004424 eye movement Effects 0.000 description 2
• 230000004907 flux Effects 0.000 description 2
• 230000037406 food intake Effects 0.000 description 2
• 235000012631 food intake Nutrition 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• 230000009395 genetic defect Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 150000002430 hydrocarbons Chemical class 0.000 description 2
• 238000005286 illumination Methods 0.000 description 2
• 125000002883 imidazolyl group Chemical group 0.000 description 2
• 238000003365 immunocytochemistry Methods 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007913 intrathecal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 230000009545 invasion Effects 0.000 description 2
• 229960002725 isoflurane Drugs 0.000 description 2
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
• 125000001786 isothiazolyl group Chemical group 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 235000010981 methylcellulose Nutrition 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 229920001206 natural gum Polymers 0.000 description 2
• 230000003988 neural development Effects 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 238000003305 oral gavage Methods 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 229960001057 paliperidone Drugs 0.000 description 2
• 239000004031 partial agonist Substances 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• 238000011458 pharmacological treatment Methods 0.000 description 2
• YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 238000010149 post-hoc-test Methods 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 125000003226 pyrazolyl group Chemical group 0.000 description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 description 2
• 125000000168 pyrrolyl group Chemical group 0.000 description 2
• SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 2
• 238000005070 sampling Methods 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 230000001953 sensory effect Effects 0.000 description 2
• 230000036306 sensory inhibition Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 239000002400 serotonin 2A antagonist Substances 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 238000002603 single-photon emission computed tomography Methods 0.000 description 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 2
• 229910052815 sulfur oxide Inorganic materials 0.000 description 2
• 230000000946 synaptic effect Effects 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• FTEZEFRVMRFCJL-UHFFFAOYSA-N (2-bromophenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC=C1Br FTEZEFRVMRFCJL-UHFFFAOYSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• LOYXEARIHRYZDG-UHFFFAOYSA-N (3-cyanophenyl)carbamic acid Chemical compound OC(=O)NC1=CC=CC(C#N)=C1 LOYXEARIHRYZDG-UHFFFAOYSA-N 0.000 description 1
• HNAXBZUMENBWSX-UHFFFAOYSA-N (3-methylphenyl)carbamic acid Chemical compound CC1=CC=CC(NC(O)=O)=C1 HNAXBZUMENBWSX-UHFFFAOYSA-N 0.000 description 1
• PHVSUUGFGMGZPE-UHFFFAOYSA-N (4-bromophenyl)carbamic acid Chemical compound OC(=O)NC1=CC=C(Br)C=C1 PHVSUUGFGMGZPE-UHFFFAOYSA-N 0.000 description 1
• OSQOGASVZHDGKF-UHFFFAOYSA-N (4-methylsulfanylphenyl)carbamic acid Chemical compound CSC1=CC=C(NC(O)=O)C=C1 OSQOGASVZHDGKF-UHFFFAOYSA-N 0.000 description 1
• TYAGAVRSOFABFO-VIFPVBQESA-N (5s)-spiro[1,3-oxazolidine-5,3'-1-azabicyclo[2.2.2]octane]-2-one Chemical compound O1C(=O)NC[C@]11C(CC2)CCN2C1 TYAGAVRSOFABFO-VIFPVBQESA-N 0.000 description 1
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
• VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
• WFPBURVJRDQRPT-UHFFFAOYSA-N 1-(3-phenoxyphenyl)-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1C=CC(OC=2C=CC=CC=2)=CC=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 WFPBURVJRDQRPT-UHFFFAOYSA-N 0.000 description 1
• STHHLVCQSLRQNI-UHFFFAOYSA-N 1-azabicyclo[3.2.1]octane Chemical compound C1C2CCN1CCC2 STHHLVCQSLRQNI-UHFFFAOYSA-N 0.000 description 1
• QAVSAAADWVRRHO-UHFFFAOYSA-N 1-benzothiophen-3-ylcarbamic acid Chemical compound C1=CC=C2C(NC(=O)O)=CSC2=C1 QAVSAAADWVRRHO-UHFFFAOYSA-N 0.000 description 1
• JBLCIQZBAQAMME-UHFFFAOYSA-N 1-naphthalen-1-yl-3-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound C=1C=CC2=CC=CC=C2C=1NC(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 JBLCIQZBAQAMME-UHFFFAOYSA-N 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
• GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 1
• POPPVIRYGJQIOF-UHFFFAOYSA-N 2-acetyloxyethyl(trimethyl)azanium;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CC(=O)OCC[N+](C)(C)C.CN1CCCC1C1=CC=CN=C1 POPPVIRYGJQIOF-UHFFFAOYSA-N 0.000 description 1
• 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
• VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
• 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
• QUUZVLSBZNXIKV-UHFFFAOYSA-N 4-phenoxy-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 QUUZVLSBZNXIKV-UHFFFAOYSA-N 0.000 description 1
• 210000002348 5-ht neuron Anatomy 0.000 description 1
• 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
• 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 229940122578 Acetylcholine receptor agonist Drugs 0.000 description 1
• 241000478345 Afer Species 0.000 description 1
• 230000007730 Akt signaling Effects 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 235000019489 Almond oil Nutrition 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 241001123248 Arma Species 0.000 description 1
• 208000036640 Asperger disease Diseases 0.000 description 1
• 201000006062 Asperger syndrome Diseases 0.000 description 1
• 241000132092 Aster Species 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• ZKPIIYAYSXXUDC-VTIBCZDNSA-N Bullatin Natural products O=C1C(CCCCCCC[C@@H](O)CCCC[C@@H](O)[C@@H]2O[C@@H]([C@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@@H](C)O1 ZKPIIYAYSXXUDC-VTIBCZDNSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 102000009660 Cholinergic Receptors Human genes 0.000 description 1
• 108010009685 Cholinergic Receptors Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 244000060011 Cocos nucifera Species 0.000 description 1
• 235000013162 Cocos nucifera Nutrition 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010052804 Drug tolerance Diseases 0.000 description 1
• 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 241000950314 Figura Species 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
• 101150104779 HTR2A gene Proteins 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 description 1
• 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
• 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• 125000000205 L-threonino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])[C@](C([H])([H])[H])([H])O[H] 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 241000763212 Lype Species 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 238000012347 Morris Water Maze Methods 0.000 description 1
• 229920000715 Mucilage Polymers 0.000 description 1
• WECKJONDRAUFDD-ZDUSSCGKSA-N N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-4-chlorobenzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)N[C@@H]1C(CC2)CCN2C1 WECKJONDRAUFDD-ZDUSSCGKSA-N 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 201000010273 Porphyria Cutanea Tarda Diseases 0.000 description 1
• 206010036467 Poverty of speech Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 108091034057 RNA (poly(A)) Proteins 0.000 description 1
• 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
• 101000606117 Rattus norvegicus Tyrosine 3-monooxygenase Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 208000020186 Schizophreniform disease Diseases 0.000 description 1
• 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
• 241000221016 Schoepfia arenaria Species 0.000 description 1
• SZKKRCSOSQAJDE-UHFFFAOYSA-N Schradan Chemical compound CN(C)P(=O)(N(C)C)OP(=O)(N(C)C)N(C)C SZKKRCSOSQAJDE-UHFFFAOYSA-N 0.000 description 1
• 244000000231 Sesamum indicum Species 0.000 description 1
• 235000003434 Sesamum indicum Nutrition 0.000 description 1
• 241001302210 Sida <water flea> Species 0.000 description 1
• 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 1
• 101710114615 Sodium-dependent dopamine transporter Proteins 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 229910000831 Steel Inorganic materials 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 101150076211 TH gene Proteins 0.000 description 1
• 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
• 241000897276 Termes Species 0.000 description 1
• 241000534944 Thia Species 0.000 description 1
• YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 description 1
• 241000613130 Tima Species 0.000 description 1
• KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
• KSYFKNNOVPCSKN-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl] n-(4-methylphenyl)carbamate Chemical compound C1=CC(C)=CC=C1NC(=O)OC1C(CC=2C=NC=CC=2)N2CCC1CC2 KSYFKNNOVPCSKN-UHFFFAOYSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 description 1
• 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 238000011360 adjunctive therapy Methods 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 230000003281 allosteric effect Effects 0.000 description 1
• 239000008168 almond oil Substances 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
• 229960003805 amantadine Drugs 0.000 description 1
• YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 230000000454 anti-cipatory effect Effects 0.000 description 1
• 229940124604 anti-psychotic medication Drugs 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 210000003050 axon Anatomy 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• FJTKCFSPYUMXJB-UHFFFAOYSA-N bevantolol hydrochloride Chemical compound [Cl-].C1=C(OC)C(OC)=CC=C1CC[NH2+]CC(O)COC1=CC=CC(C)=C1 FJTKCFSPYUMXJB-UHFFFAOYSA-N 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• ZKPIIYAYSXXUDC-UHFFFAOYSA-N bullatin Chemical compound O1C(C(O)CCCCCCCCCC)CCC1C1OC(C(O)CCCCC(O)CCCCCCCC=2C(OC(C)C=2)=O)CC1 ZKPIIYAYSXXUDC-UHFFFAOYSA-N 0.000 description 1
• 229910052792 caesium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 125000004432 carbon atom Chemical group C* 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 210000005056 cell body Anatomy 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 210000004081 cilia Anatomy 0.000 description 1
• WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 230000037411 cognitive enhancing Effects 0.000 description 1
• 230000003920 cognitive function Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 229940075591 dalay Drugs 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000001739 density measurement Methods 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
• 210000005064 dopaminergic neuron Anatomy 0.000 description 1
• 210000001029 dorsal striatum Anatomy 0.000 description 1
• 238000012137 double-staining Methods 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 238000003255 drug test Methods 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 238000000835 electrochemical detection Methods 0.000 description 1
• 230000007608 epigenetic mechanism Effects 0.000 description 1
• 230000001073 episodic memory Effects 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000002964 excitative effect Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 230000000193 eyeblink Effects 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000834 fixative Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000020375 flavoured syrup Nutrition 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• GOLHZPOXCLTFRB-UHFFFAOYSA-N furan-3-carboxamide Chemical compound NC(=O)C=1C=COC=1 GOLHZPOXCLTFRB-UHFFFAOYSA-N 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 230000003371 gabaergic effect Effects 0.000 description 1
• DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
• 230000000574 ganglionic effect Effects 0.000 description 1
• 238000003304 gavage Methods 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• 229940049906 glutamate Drugs 0.000 description 1
• 210000001362 glutamatergic neuron Anatomy 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 244000144993 groups of animals Species 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 230000026781 habituation Effects 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 230000006195 histone acetylation Effects 0.000 description 1
• QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 238000012744 immunostaining Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 229910052743 krypton Inorganic materials 0.000 description 1
• DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 231100000636 lethal dose Toxicity 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 230000006742 locomotor activity Effects 0.000 description 1
• 230000027928 long-term synaptic potentiation Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• 230000036244 malformation Effects 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 230000006386 memory function Effects 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
• 229960003105 metformin Drugs 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000036651 mood Effects 0.000 description 1
• 230000008450 motivation Effects 0.000 description 1
• 230000037023 motor activity Effects 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• DRHOWMRJAGBUHY-UHFFFAOYSA-N naphthalen-2-ylcarbamic acid Chemical compound C1=CC=CC2=CC(NC(=O)O)=CC=C21 DRHOWMRJAGBUHY-UHFFFAOYSA-N 0.000 description 1
• UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 229940105631 nembutal Drugs 0.000 description 1
• 230000010004 neural pathway Effects 0.000 description 1
• 208000004296 neuralgia Diseases 0.000 description 1
• 230000001722 neurochemical effect Effects 0.000 description 1
• 230000004031 neuronal differentiation Effects 0.000 description 1
• 230000007514 neuronal growth Effects 0.000 description 1
• 208000021722 neuropathic pain Diseases 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 230000003557 neuropsychological effect Effects 0.000 description 1
• 230000003957 neurotransmitter release Effects 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
• 238000010525 oxidative degradation reaction Methods 0.000 description 1
• DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
• NUSQOFAKCBLANB-UHFFFAOYSA-N phthalocyanine tetrasulfonic acid Chemical compound C12=CC(S(=O)(=O)O)=CC=C2C(N=C2NC(C3=CC=C(C=C32)S(O)(=O)=O)=N2)=NC1=NC([C]1C=CC(=CC1=1)S(O)(=O)=O)=NC=1N=C1[C]3C=CC(S(O)(=O)=O)=CC3=C2N1 NUSQOFAKCBLANB-UHFFFAOYSA-N 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000011505 plaster Substances 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 230000002360 prefrontal effect Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000003518 presynaptic effect Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000004800 psychological effect Effects 0.000 description 1
• CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000004080 punching Methods 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
• 150000008584 quinuclidines Chemical class 0.000 description 1
• 239000002287 radioligand Substances 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 101150110872 ric-3 gene Proteins 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• SIIICDNNMDMWCI-YJNKXOJESA-N rti-55 Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@H]2C(=O)OC)=CC=C(I)C=C1 SIIICDNNMDMWCI-YJNKXOJESA-N 0.000 description 1
• 230000004434 saccadic eye movement Effects 0.000 description 1
• 229940124711 schizophrenia therapeutics Drugs 0.000 description 1
• 229940125723 sedative agent Drugs 0.000 description 1
• 239000000932 sedative agent Substances 0.000 description 1
• 238000007391 self-medication Methods 0.000 description 1
• UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
• 229960004425 sibutramine Drugs 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 229940080313 sodium starch Drugs 0.000 description 1
• 230000006886 spatial memory Effects 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000010959 steel Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000035900 sweating Effects 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 210000001587 telencephalon Anatomy 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
• 210000001103 thalamus Anatomy 0.000 description 1
• VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea group Chemical group NC(=S)N UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 229960004394 topiramate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
• TUCIOBMMDDOEMM-RIYZIHGNSA-N tyrphostin B42 Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 210000005111 ventral hippocampus Anatomy 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1